You are here

FDA Approves Duloxetine for Stress Urinary Incontinence

INDIANAPOLIS, IN -- September 3, 2003 -- Eli Lilly and Company has received an approvable letter from the U.S. Food and Drug Administration's Division of Reproductive and Urologic Drug Products (DRUDP) for duloxetine for the treatment of stress urinary incontinence (SUI). Final FDA approval is contingent upon successful completion of additional acute pre-clinical and clinical pharmacology studies; satisfactory resolution of manufacturing issues at Lilly's Indianapolis manufacturing facilities, including the satisfactory completion of a pre-approval site inspection; and completion of label negotiations.

Lilly plans to conduct discussions with the FDA concerning the company's plans to provide the information the agency has requested. The results of these discussions will allow the company to provide a better estimate of the potential U.S. approval date. Currently, pending more precise information, Lilly anticipates a U.S. approval of duloxetine for SUI in late 2004 or the first half of 2005.

Duloxetine for depression, known as CymbaltaTM, is also currently under review by the FDA's Division of Neuropharmacologic Drug Products. Lilly received an approvable letter from the FDA for Cymbalta in September 2002. As of this date, the Division of Neuropharmacologic Drug Products has not communicated to Lilly the extent to which the requests made by DRUDP, in the approvable letter for duloxetine for SUI, will affect the review and approval of Cymbalta. Lilly expects to have more clarity on the timing of the approval of Cymbalta by the action date prior to the end of this year.

"We are committed to bringing our innovative late stage products as quickly as possible to the patients who need them," said Sidney Taurel, chairman, president and chief executive officer, Eli Lilly and Company. "To that end, we will work rapidly to provide the additional data requested by the agency and to resolve our outstanding manufacturing issues."

On Friday Sept. 5, Lilly is convening its annual investment community meeting where senior management will discuss these products as well as others in the company's late-stage pipeline. The meeting, held from 8:30 a.m. to 1:30 p.m. Eastern Time, will be webcast live at and will be available for replay through Sept. 19, 2003.

In November 2002, Lilly and Boehringer Ingelheim signed a long-term agreement to jointly develop and commercialize duloxetine hydrochloride. Duloxetine is currently being developed for the treatment of stress urinary incontinence (SUI) and depression. This partnership covers most countries worldwide with few exceptions. In the United States, the collaboration is for SUI only.

About SUI and duloxetine
Stress urinary incontinence is a medical condition primarily affecting women, attributed to insufficient closure of the urethral sphincter muscle (at the bladder outlet). For SUI sufferers, accidental urine leakage results when there is an increase in pressure in the abdomen - such as when laughing, coughing, sneezing, lifting or exercising. SUI symptoms affect an estimated one in three women in the United States1. Unfortunately many women do not seek treatment because they are embarrassed, fear surgery, or believe SUI is a normal part of aging and that nothing can be done about it. Primary causes and risk factors of SUI are nerve damage, muscle damage or weakness, childbirth, obesity, chronic coughing and constipation. Once approved, duloxetine would become the first pharmaceutical indicated to treat SUI.

Duloxetine is a dual reuptake inhibitor of the neurotransmitters serotonin and norepinephrine, which are believed to play key roles in the normal closure of muscle at the base of the bladder. Increased neurotransmitter concentration in turn stimulates increased activity of the nerve that stimulates the urethral sphincter. This stimulation is believed to increase the tone of the urethral sphincter at the exit of the bladder, thereby helping prevent accidental urine leakage due to physical activity.

Source: Eli Lilly and Company

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs